GBA1突变携带者多巴胺合成的纵向PET研究
横断面和纵向比较均发现帕金森病显著效应,但无帕金森综合征的突变携带者基线及随访期间纹状体摄取与对照无显著差异。
要点
- GBA1突变携带者中,无帕金森综合征者纹状体[18F]-氟多巴摄取与对照无显著差异。
- 帕金森综合征对纹状体[18F]-氟多巴摄取及其变化有显著影响。
- 纵向设计有助于评估GBA1突变携带者早期多巴胺能变化。
核心结论
- 无帕金森综合征的GBA1突变携带者基线及纵向纹状体[18F]-氟多巴摄取与对照无显著差异。
主要发现
- 横断面和纵向比较Ki及Ki变化均发现帕金森病显著效应。
- 无帕金森综合征的突变携带者基线及随访期间纹状体[18F]-氟多巴摄取与对照无显著差异。
临床怎么用
- 对于无帕金森综合征的GBA1突变携带者,[18F]-氟多巴PET未见明显多巴胺合成下降,提示该指标可能不适用于早期筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in GBA1, the gene mutated in Gaucher disease, are a common genetic risk factor for Parkinson disease, although the penetrance is low. We performed [18 F]-fluorodopa positron emission tomography studies of 57 homozygous and heterozygous GBA1 mutation carriers (15 with parkinsonism) and 98 controls looking for early indications of dopamine loss using voxelwise analyses to identify group differences in striatal [18 F]-fluorodopa uptake (Ki ). Forty-eight subjects were followed longitudinally. Cross-sectional and longitudinal comparisons of Ki and Ki change found significant effects of Parkinson disease. However, at baseline and over time, striatal [18 F]-fluorodopa uptake in mutation carriers without parkinsonism did not significantly differ from controls. ANN NEUROL 2020;87:652-657.
引用
- Lopez G, Eisenberg DP, Gregory MD, et al. Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with GBA1 Mutations. Ann Neurol. 2020. PMID: 32030791. doi:10.1002/ana.25692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。